HISTOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2 USD | 0.00% |
|
0.00% | -35.00% |
| 19/04 | Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc. | CI |
| 18/04 | Histogen Inc. Filed for Bankruptcy | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 1.03M 86.13M | Sales 2022 | 3.77M 315M | Capitalization | 3.55M 296M |
|---|---|---|---|---|---|
| Net income 2021 | -15M -1.25B | Net income 2022 | -10M -835M | EV / Sales 2021 | 2.62 x |
| Net cash position 2021 | 13.92M 1.16B | Net cash position 2022 | 7.48M 624M | EV / Sales 2022 | -1.04 x |
| P/E ratio 2021 |
-0.85
x | P/E ratio 2022 |
-0.24
x | Employees | 7 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| Current month | -43.04% | ||
| 1 month | -60.00% | ||
| 3 months | -41.18% | ||
| 6 months | -36.51% | ||
| Current year | -35.00% |
1 week
0.20
0.20
1 month
0.050.50
Current year
0.050.55
1 year
0.051.05
3 years
0.0524.60
5 years
0.05105.24
10 years
0.05105.24
| Managers | Title | Age | Since |
|---|---|---|---|
Susan Knudson
CEO | Chief Executive Officer | 60 | 27/20/27 |
Mark A. Hubka
CTO | Chief Tech/Sci/R&D Officer | - | - |
Thomas L. Hubka
PRN | Corporate Officer/Principal | 37 | 26/20/26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Kisner
CHM | Chairman | 77 | 01/14/01 |
| Director/Board Member | 54 | 25/21/25 | |
David Crean
BRD | Director/Board Member | 59 | 26/20/26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/24/15 | 0.2 | 0.00% | 209 |
| 10/24/10 | 0.2 | 0.00% | 170 |
| 08/24/08 | 0.2 | +25.00% | 735 |
| 07/24/07 | 0.16 | +6.67% | 424 |
Delayed Quote OTC Markets, May 15, 2024 at 07:00 pm IST
More quotes
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâs natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.00% | 854K | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| +0.99% | 22.27B | |
| -12.64% | 22.22B | |
| -5.48% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +7.77% | 14.29B | |
| +37.41% | 12.52B |
- Stock Market
- Equities
- HSTO Stock